Tables S7-S8 from The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)
posted on 2023-03-31, 19:50authored byDara L. Aisner, Lynette M. Sholl, Lynne D. Berry, Michael R. Rossi, Heidi Chen, Junya Fujimoto, Andre L. Moreira, Suresh S. Ramalingam, Liza C. Villaruz, Gregory A. Otterson, Eric Haura, Katerina Politi, Bonnie Glisson, Jeremy Cetnar, Edward B. Garon, Joan Schiller, Saiama N. Waqar, Lecia V. Sequist, Julie Brahmer, Yu Shyr, Kelly Kugler, Ignacio I. Wistuba, Bruce E. Johnson, John D. Minna, Mark G. Kris, Paul A. Bunn, David J. Kwiatkowski
Supplemental Table 7: Cases with two or more oncogenic driver alterations. Supplemental Table 8. Comparison of LCMC I and LCMC II.